PRIMARY STUDY
The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity
Key Findings: This review finds evidence that the endocannabinoid system (ECS) plays an important role in inflammation, especially in gastric inflammatory diseases, and cannabinoid agonists and ECS inhibitors could provide therapeutic targets for treatment.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): Belgium
Year of Pub: 2012
Cannabinoids Studied: Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: GPCR
Citation: Alhouayek M and Muccioli GG. The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med. 2012; 18:615-25. doi: 10.1016/j.molmed.2012.07.009
Authors: Alhouayek M, Muccioli GG
